New concepts in herpes simplex virus vaccine development: Notes from the battlefield

Expert Review of Vaccines

Volumn 8, Issue 8, 2009, Pages 1023-1035

  Dasgupta, Gargi ^a   Chentoufi, Aziz Alami ^a   Nesburn, Anthony B ^a   Wechsler, Steven L ^a   BenMohamed, Lbachir ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Building 55 ^*  (United States)

Author keywords

Animal model; Asymptomatic; Clinical trial; Epitope; Genital herpes; Herpes simplex virus; Immunoprophylactic; Immunotherapeutic; Lipopeptide; Ocular herpes; Symptomatic; Vaccine

Indexed keywords

EPITOPE; GLYCOPROTEIN B; GLYCOPROTEIN D; HERPES SIMPLEX VACCINE; ICP 0 PROTEIN; INACTIVATED VACCINE; LIPOPEPTIDE; LIVE VACCINE; MEMBRANE PROTEIN; UL 25 PROTEIN; UL 27 PROTEIN; UL 39 PROTEIN; UL 46 PROTEIN; UL 47 PROTEIN; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN RECOGNITION; BLINDNESS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COST EFFECTIVENESS ANALYSIS; CROSS REACTION; DENDRITIC CELL; DRUG COST; DRUG MANUFACTURE; DRUG PURIFICATION; DRUG SAFETY; EXPERIMENTAL MODEL; GENITAL HERPES; HERPES; HERPES SIMPLEX KERATITIS; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IMMUNOPATHOGENESIS; IMMUNOPATHOLOGY; INNATE IMMUNITY; MEMORY T LYMPHOCYTE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEXUALLY TRANSMITTED DISEASE; T LYMPHOCYTE; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS TRANSMISSION;

EPITOPES; HERPES GENITALIS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS VACCINES; HERPESVIRUS 1, HUMAN; HERPESVIRUS 2, HUMAN; HUMANS; LIPOPEPTIDES; T-LYMPHOCYTES;

EID: 68049127746     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.09.60     Document Type: Review

References (99)

1. Deprez B, Sauzet JP, Boutillon C et al. Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL. Vaccine 14(5), 375-382 (1996).
2. Sauzet JP, Deprez B, Martinon F, Guillet JG, Gras-Masse H, Gomard E. Longlasting anti-viral cytotoxic T lymphocytes induced in vivo with chimericmultirestricted lipopeptides. Vaccine 13(14), 1339-1345 (1995).
3. Sette A, Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 50(3-4), 201-212 (1999).
4. BenMohamed L, Thomas A, Druilhe P. Long-term multiepitopic cytotoxic- T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides. Infect. Immun. 72(8), 4376-4384 (2004).
5. Zhu X, Ramos TV, Gras-Masse H, Kaplan BE, BenMohamed L. Lipopeptide epitopes extended by ne-palmitoyl lysine moiety increases uptake and maturation of dendritic cell through a Toll-like receptor 2 pathway and triggers a Th1-dependent protective immunity. Eur. J. Immunol. 34(5), 1142-1149 (2004).
6. Bettahi I, Zhang X, Afifi RE, BenMohamed L. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response. Viral Immunol. 19(2), 220-236 (2006).
7. Jones CA, Cunningham AL. Vaccination strategies to prevent genital herpes and neonatal herpes simplex virus (HSV) disease. Herpes 11(1), 12-17 (2004).
8. Gebhardt BM, Kaufman HE, Hill JM. Effect of acyclovir on thermal stressinduced herpesvirus reactivation. Curr. Eye Res. 29(2-3), 137-144 (2004).
9. Koelle DM, Corey L. Recent progress in herpes simplex virus immunobiology and vaccine research. Clin. Microbiol. Rev. 16(1), 96-113 (2003).
10. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 11(Suppl. 1), 24A-35A (2004).
11. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J. Infect. Dis. 185(1), 45-52 (2002). •• One of the first reviews that highlights how genital herpes simplex virus (HSV) HSV-2 infection affects HIV acquisition.
12. Corey L, Wald A, Celum CL, Quinn TC. The effects of herpes simplex virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. J. Acquir. Immune Defic. Syndr. 35(5), 435-445 (2004). • Another review that links ulcerative HSV-2 with HIV-1 acquisition and transmission.
13. Zhang X, Chentoufi AA, Dasgupta G et al. A genital tract peptide epitope vaccine targeting TLR-2 efficiently induces local and systemic CD8+ T cells and protects against herpes simplex virus type 2 challenge. Muc. Immunol. 180(1), 426-437 (2009). •• The first paper showing that peptide epitopes extended with an agonist of Toll-like receptor-2, which are abundantly expressed by dendritic and epithelial cells of the vaginal mucosa, induced a strong and long lasting protective immunity against genital herpes in mice.
14. Karunakaran KP, Rey-Ladino J, Stoynov N et al. Immunoproteomic discovery of novel T cell antigens from the obligate intracellular pathogen Chlamydia. J. Immunol. 180(4), 2459-2465 (2008).
15. Rajcani J, Durmanova V. Developments in herpes simplex virus vaccines: old problems and new challenges. Folia Microbiol. (Praha) 51(2), 67-85 (2006).
16. Manservigi R, Boero A, Argnani R et al. Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model. Vaccine 23(7), 865-872 (2005).
17. Zhang X, Castelli FA, Zhu X, Wu M, Maillere B, BenMohamed L. Genderdependent HLA-DR-restricted epitopes identified from herpes simplex virus type 1 glycoprotein D. Clin. Vaccine Immunol. 15(9), 1436-1449 (2008). • First paper to reveal a gender-dependent T-cell response to a discrete set of HSV-1 and HSV-2 human epitopes, and suggests that gender should be taken into account during evaluations of herpes vaccines.
18. Bettahi I, Nesburn AB, Yoon S et al. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines. Invest. Ophthalmol. Vis. Sci. 48(10), 4643-4653 (2007).
19. Nesburn AB, Bettahi I, Zhang X et al. Topical/mucosal delivery of sub-unit vaccines that stimulate the ocular mucosal immune system. Ocul. Surf. 4(4), 178-187 (2006).
20. Zhang X, Issagholian A, Berg EA, Fishman JB, Nesburn AB, BenMohamed L. Th-cytotoxic T-lymphocyte chimeric epitopes extended by Nepsilon-palmitoyl lysines induce herpes simplex virus type 1-specific effector CD8+ Tc1 responses and protect against ocular infection. J. Virol. 79(24), 15289-15301 (2005). •• First, original paper that demonstrated the preclinical immunogenicity and protective efficacy of a palmitoyl-tailed T-helper cytotoxic T lymphocyte chimeric epitope-based vaccine against ocular herpes infection.
21. Trottier H, Franco EL. The epidemiology of genital human papillomavirus infection. Vaccine 24(Suppl. 1), S1-S15 (2006).
22. Cunningham AL, Diefenbach RJ, Miranda-Saksena M et al. The cycle of human herpes simplex virus infection: virus transport and immune control. J. Infect. Dis. 194(Suppl. 1), S11-S18 (2006).
23. Bernstein D. Glycoprotein D adjuvant herpes simplex virus vaccine. Expert Rev. Vaccines 4(5), 615-627 (2005).
24. Knickelbein JE, Khanna KM, Yee MB, Baty CJ, Kinchington PR, Hendricks RL. Noncytotoxic lytic granule-mediated CD8+ T cell inhibition of HSV-1 reactivation from neuronal latency. Science 322(5899), 268-271 (2008). •• First paper showing a nonlethal mechanism of viral inactivation in which the lytic granule component, granzyme B, degrades the HSV-1 immediate-early protein, ICP4, which is essential for further viral gene expression.
25. Hallett TB, Aberle-Grasse J, Bello G et al. Declines in HIV prevalence can be associated with changing sexual behaviour in Uganda, urban Kenya, Zimbabwe, and urban Haiti. Sex Transm. Infect. 82(Suppl. 1), i1-i8 (2006).
26. Kaufman HE, Azcuy AM, Varnell ED, Sloop GD, Thompson HW, Hill JM. HSV-1 DNA in tears and saliva of normal adults. Invest. Ophthalmol. Vis. Sci. 46(1), 241-247 (2005).
27. Leone P. Reducing the risk of transmitting genital herpes: advances in understanding and therapy. Curr. Med. Res. Opin. 21(10), 1577-1582 (2005).
28. Toma HS, Murina AT, Areaux RG Jr et al. Ocular HSV-1 latency, reactivation and recurrent disease. Semin. Ophthalmol. 23(4), 249-273 (2008).
29. Shu CJ, Radu CG, Shelly SM et al. Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanomaexpressed self-antigen. Int. Immunol. 21(2), 155-165 (2009).
30. Sheridan BS, Cherpes TL, Urban J, Kalinski P, Hendricks RL. Reevaluating the CD8 T-cell response to herpes simplex virus type 1: involvement of CD8 T cells reactive to subdominant epitopes. J. Virol. 83(5), 2237-2245 (2009).
31. Muller WJ, Dong L, Vilalta A et al. Herpes simplex virus type 2 tegument proteins contain subdominant T-cell epitopes detectable in BALB/c mice after DNA immunization and infection. J. Gen. Virol. 90(Pt 5), 1153-1163 (2009).
32. Taylor BS, Pal M, Yu J et al. Humoral response profiling reveals pathways to prostate cancer progression. Mol. Cell. Proteomics 7(3), 600-611 (2008).
33. Divito S, Cherpes TL, Hendricks RL. A triple entente: virus, neurons, and CD8+ T cells maintain HSV-1 latency. Immunol. Res. 36(1-3), 119-126 (2006).
34. Mott KR, Chentoufi AA, Carpenter D, Benmohamed L, Wechsler S, Ghiasi H. A glycoprotein K (gK) CD8+ T-cell epitope of herpes simplex virus types 1 and 2 increases ocular virus replication and pathogenicity. Invest. Ophthalmol. Vis. Sci. 50(6), 2903-2912 (2009).
35. Nesburn AB, Bettahi I, Dasgupta G et al. Functional Foxp3+ CD4+ CD25(bright+) 'natural' regulatory T cells are abundant in rabbit conjunctiva and suppress virusspecific CD4+ and CD8+ effector T cells during ocular herpes infection. J. Virol. 81(14), 7647-7661 (2007).
36. Nesburn AB, Ramos TV, Zhu X, Asgarzadeh H, Nguyen V, BenMohamed L. Local and systemic B cell and Th1 responses induced following ocular mucosal delivery of multiple epitopes of herpes simplex virus type 1 glycoprotein D together with cytosine-phosphate-guanine adjuvant. Vaccine 23(7), 873-883 (2005).
37. Hu J, Peng X, Schell TD, Budgeon LR, Cladel NM, Christensen ND. An HLA-A2.1-transgenic rabbit model to study immunity to papillomavirus infection. J. Immunol. 177(11), 8037-8045 (2006).
38. Malkin JE. Epidemiology of genital herpes simplex virus infection in developed countries. Herpes 11(Suppl. 1), 2A-23A (2004).
39. Roberts CM, Pfister JR, Spear SJ. Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students. Sex. Transm. Dis. 30(10), 797-800 (2003).
40. Abu-Raddad LJ, Magaret AS, Celum C et al. Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa. PLoS ONE 3(5), e2230 (2008). •• Indicates that the HSV-2 role as a biological cofactor in HIV acquisition and transmission and may have contributed substantially to AIDS, particularly by facilitating HIV spread among the low-risk population with stable long-term sexual partnerships in Africa.
41. Wald A, Schacker T, Corey L. HSV-2 and HIV: consequences of an endemic opportunistic infection. STEP Perspect. 9(3), 2-4 (1997).
42. Hirbod T, Broliden K, Kaul R. Genital immunoglobulin A and HIV-1 protection: virus neutralization versus specificity. Aids 22(17), 2401-2402 (2008).
43. Gill N, Davies EJ, Ashkar AA. The role of toll-like receptor ligands/agonists in protection against genital HSV-2 infection. Am. J. Reprod. Immunol. 59(1), 35-43 (2008).
44. Friedman SR, Bolyard M, Sandoval M, Mateu-Gelabert P, Maslow C, Zenilman J. Relative prevalence of different sexually transmitted infections in HIV-discordant sexual partnerships: data from a risk network study in a high-risk New York neighbourhood. Sex. Transm. Infect. 84(1), 17-18 (2008).
45. Zuckerman RA, Lucchetti A, Whittington WL et al. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/ HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial. J. Infect. Dis. 196(10), 1500-1508 (2007).
46. Strick LB, Wald A, Celum C. Management of herpes simplex virus type 2 infection in HIV type 1-infected persons. Clin. Infect. Dis. 43(3), 347-356 (2006).
47. Sacks SL, Griffiths PD, Corey L et al. Introduction: is viral shedding a surrogate marker for transmission of genital herpes? Antiviral Res. 63(Suppl. 1), S3-S9 (2004).
48. Koelle DM. Vaccines for herpes simplex virus infections. Curr. Opin Investig. Drugs 7(2), 136-141 (2006).
49. Smith TJ, Morrison LA, Leib DA. Pathogenesis of herpes simplex virus type 2 virion host shutoff (vhs) mutants. J. Virol. 76(5), 2054-2061 (2002).
50. Bourne N, Bravo FJ, Francotte M et al. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J. Infect. Dis. 187(4), 542-549 (2003).
51. Stanberry LR, Spruance SL, Cunningham AL et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347(21), 1652-1661 (2002). •• Describes the largest recent clinical trial using a recombinant HSV-2. The vaccine study showed that the glycoprotein D recombinant vaccine has efficacy against genital herpes in women who are seronegative for both HSV-1 and HSV-2, but not in women who are seropositive for HSV-1 and seronegative for HSV-2. It had no efficacy in men.
52. Natuk RJ, Cooper D, Guo M et al. Recombinant vesicular stomatitis virus vectors expressing herpes simplex virus type 2 gD elicit robust CD4+ Th1 immune responses and are protective in mouse and guinea pig models of vaginal challenge. J. Virol. 80(9), 4447-4457 (2006).
53. Koelle DM, Ghiasi H. Prospects for developing an effective vaccine against ocular herpes simplex virus infection. Curr. Eye Res. 30(11), 929-942 (2005).
54. Bowers WJ, Mastrangelo MA, Stanley HA, Casey AE, Milo LJ Jr, Federoff HJ. HSV amplicon-mediated Abeta vaccination in Tg2576 mice: differential antigen-specific immune responses. Neurobiol. Aging 26(4), 393-407 (2005).
55. Toka FN, Rouse BT. Mucosal application of plasmid-encoded IL-15 sustains a highly protective anti-herpes simplex virus immunity. J. Leukoc. Biol. 78(1), 178-186 (2005).
56. Toka FN, Gierynska M, Suvas S, Schoenberger SP, Rouse BT. Rescue of memory CD8+ T cell reactivity in peptide/ TLR9 ligand immunization by codelivery of cytokines or CD40 ligation. Virology 331(1), 151-158 (2005).
57. Toka FN, Gierynska M, Suvas S, Schoenberger SP, Rouse BT. Rescue of memory CD8+ T cell reactivity in peptide/ TLR9 ligand immunization by codelivery of cytokines or CD40 ligation. Virology 331(1), 151-158 (2005).
58. Tengvall S, Josefsson A, Holmgren J, Harandi AM. CpG oligodeoxynucleotide augments HSV-2 glycoprotein D DNA vaccine efficacy to generate T helper 1 response and subsequent protection against primary genital herpes infection in mice. J. Reprod. Immunol. 68(1-2), 53-69 (2005).
59. Osorio Y, Ghiasi H. Recombinant herpes simplex virus type 1 (HSV-1) codelivering interleukin-12p35 as a molecular adjuvant enhances the protective immune response against ocular HSV-1 challenge. J. Virol. 79(6), 3297-3308 (2005).
60. Hosken NA. Development of a therapeutic vaccine for HSV-2. Vaccine 23(17-18), 2395-2398 (2005).
61. Kallio-Laine K, Seppanen M, Lokki ML et al. Widespread unilateral pain associated with herpes simplex virus infections. J. Pain 9(7), 658-665 (2008).
62. Hoshino Y, Dalai SK, Wang K et al. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. J. Virol. 79(1), 410-418 (2005).
63. Hosken N, McGowan P, Meier A et al. Diversity of the CD8+ T-cell response to herpes simplex virus type 2 proteins among persons with genital herpes. J. Virol. 80(11), 5509-5515 (2006). •• First study indicating that the magnitude and breadth of the CD8+ T-cell response in HSV-2-infected population were greater than previously appreciated.
64. Chentoufi AA, Binder NR, Berka N et al. Asymptomatic human CD4+ cytotoxic T-cell epitopes identified from herpes simplex virus glycoprotein B. J. Virol. 82(23), 11792-11802 (2008). •• Describes for the first time that T cells from HSV-seropositive symptomatic and asymptomatic individuals recognize discrete nonoverlapping human epitopes on a herpes antigen.
65. Johnson AJ, Chu CF, Milligan GN. Effector CD4+ T cell involvement in clearance of infectious herpes simplex virus type 1 from sensory ganglia and spinal cords. J. Virol. 82(19), 9678-9688 (2008).
66. Posavad CM, Koelle DM, Corey L. High frequency of CD8+ cytotoxic T lymphocyte precursors specific for herpes simplex viruses in persons with genital herpes. J. Virol. 70, 8165-8168 (1996).
67. Masopust D, Vezys V, Marzo A L, Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 291, 2413-2417 (2001).
68. Hogan RJ, Zhong W, Usherwood EJ, Cookenham,T, Roberts AD, Woodland DL. Protection from respiratory virus infections can be mediated by antigenspecific CD4(+) T cells that persist in the lungs. J. Exp. Med. 193, 981-986 (2001).
69. Wiley JA, Hogan RJ, Woodland DL, Harmsen AG. Antigen-specific CD8(+) T cells persist in the upper respiratory tract following influenza virus infection. J. Immunol. 167, 3293-3299 (2001).
70. Welsh RM, Selin LK. No one is naive: the significance of heterologous T-cell immunity. Nat. Rev. Immunol. 2(6), 417-426 (2002).
71. Selin LK, Brehm MA, Naumov YN et al. Memory of mice and men: CD8+ T-cell cross-reactivity and heterologous immunity. Immunol. Rev. 211, 164-181 (2006).
72. Cornberg M, Chen AT, Wilkinson LA et al. Narrowed TCR repertoire and viral escape as a consequence of heterologous immunity. J. Clin. Invest. 116(5), 1443-1456 (2006).
73. Sabel MS, Hess SD, Egilmez NK, Conway TF Jr, Chen FA, Bankert RB. CTLA-4 blockade augments human T lymphocytemediated suppression of lung tumor xenografts in SCID mice. Cancer Immunol. Immunother. 54(10), 944-952 (2005).
74. Russell MW. Immunization for protection of the reproductive tract: a review. Am. J. Reprod. Immunol. 47(5), 265-268 (2002).
75. Kaul R, Pettengell C, Sheth PM et al. The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. J. Reprod. Immunol. 77(1), 32-40 (2007).
76. MasCasullo V, Fam E, Keller MJ, Herold BC. Role of mucosal immunity in preventing genital herpes infection. Viral Immunol. 18(4), 595-606 (2005).
77. Milligan GN, Dudley-McClain KL, Chu CF, Young CG. Efficacy of genital T cell responses to herpes simplex virus type 2 resulting from immunization of the nasal mucosa. Virology 318(2), 507-515 (2004).
78. Kwant A, Rosenthal KL. Intravaginal immunization with viral subunit protein plus CpG oligodeoxynucleotides induces protective immunity against HSV-2. Vaccine 22(23-24), 3098-3104 (2004).
79. Hamajima K, Hoshino Y, Xin KQ, Hayashi F, Tadokoro K, Okuda K. Systemic and mucosal immune responses in mice after rectal and vaginal immunization with HIV-DNA vaccine. Clin. Immunol. 102(1), 12-18 (2002).
80. Renaudet O, BenMohamed L, Dasgupta G, Bettahi I, Dumy P. Towards a self-adjuvanting multivalent B and T cell epitope containing synthetic glycolipopeptide cancer vaccine. ChemMedChem 2(7), 425-431 (2008).
81. BenMohamed L, Wechsler SL, Nesburn AB. Lipopeptide vaccines - yesterday, today, and tomorrow. Lancet Infect. Dis. 2(7), 425-431 (2002). •• Addresses the past of lipopeptide vaccines, highlights the progress made toward their optimization, and stresses future challenges and issues related to their synthesis, formulation and delivery.
82. BenMohamed L, Krishnan R, Auge C, Primus JF, Diamond DJ. Intranasal administration of a synthetic lipopeptide without adjuvant induces systemic immune responses. Immunology 106(1), 113-121 (2002).
83. BenMohamed L, Belkaid Y, Loing E, Brahimi K, Gras-Masse H, Druilhe P. Systemic immune responses induced by mucosal administration of lipopeptides without adjuvant. Eur. J. Immunol. 32(8), 2274-2281 (2002).
84. BenMohamed L, Krishnan R, Longmate J et al. Induction of CTL response by a minimal epitope vaccine in HLA A*0201/ DR1 transgenic mice: dependence on HLA class II restricted T(h) response. Hum. Immunol. 61(8), 764-779 (2000).
85. BenMohamed L, Thomas A, Bossus M et al. High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. Vaccine 18(25), 2843-2855 (2000).
86. Langhans B, Braunschweiger I, Schweitzer S, Sauerbruch T, Spengler U. Primary immunisation of hepatitis C virus (HCV)-specific antibody producing B cells by lipidated peptides. Vaccine 22(11-12), 1441-1447 (2004).
87. Launay O, Durier C, Desaint C et al. Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial. PLoS ONE 2(1), e725 (2007).
88. Gahery H, Daniel N, Charmeteau B et al. New CD4+ and CD8+ T cell responses induced in chronically HIV type-1- infected patients after immunizations with an HIV type 1 lipopeptide vaccine. AIDS Res. Hum. Retroviruses 22(7), 684-694 (2006).
89. Durier C, Launay O, Meiffredy V et al. Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults. Aids 20(7), 1039-1049 (2006).
90. Gahery H, Choppin J, Bourgault I, Fischer E, Maillere B, Guillet JG. HIV preventive vaccine research at the ANRS: the lipopeptide vaccine approach. Therapie 60(3), 243-248 (2005).
91. De Felipe C, Herrero JF, O'Brien JA et al. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 392(6674), 394-397 (1998).
92. Boursnell ME, Entwisle C, Blakeley D et al. A genetically inactivated herpes simplex virus type 2 (HSV-2) vaccine provides effective protection against primary and recurrent HSV-2 disease. J. Infect. Dis. 175(1), 16-25 (1997).
93. Scriba M. Protection of guinea pigs against primary and recurrent genital herpes infections by immunization with live heterologous or homologous herpes simplex virus: implications for a herpes virus vaccine. Med. Microbiol. Immunol. (Berl.) 166(1-4), 63-69 (1978).
94. Barsam CA, Brick DJ, Jones C, Wechsler SL, Perng GC. A viral model for corneal scarring and neovascularization following ocular infection of rabbits with a herpes simplex virus type 1 (HSV-1) mutant. Cornea 24(4), 460-466 (2005).
95. Mott KR, Osorio N, Jin L et al. The bovine herpesvirus-1 LR ORF2 is critical for this gene's ability to restore the high wild-type reactivation phenotype to a herpes simplex virus-1 LAT null mutant. J. Gen. Virol. 84(Pt 11), 2975-2985 (2003).
96. Bernstein DI, Stanberry LR. Herpes simplex virus vaccines. Vaccine 17(13-14), 1681-1689 (1999).
97. Stanberry LR. Herpes simplex virus vaccines as immunotherapeutic agents. Trends Microbiol. 3(6), 244-247 (1995).
98. Kurt-Jones EA, Chan M, Zhou S et al. Herpes simplex virus 1 interaction with Toll-like receptor 2 contributes to lethal encephalitis. Proc. Natl Acad. Sci. USA 101(5), 1315-1320 (2004).
99. Zhou S, Kurt-Jones EA, Mandell L et al. MyD88 is critical for the development of innate and adaptive immunity during acute lymphocytic choriomeningitis virus infection. Eur. J. Immunol. 35(3), 822-830 (2005).